Significant investments and developments are underway to boost biomanufacturing and life sciences infrastructure globally. GenesisM has commenced construction of a 154,000 square-foot Class A biomanufacturing facility in Greater Boston, designed to support multiple tenants with flexible regulated suites. Meanwhile, Thermo Fisher Scientific has agreed to acquire Sanofi's steriles manufacturing site in New Jersey to expand U.S. manufacturing capacity. These initiatives aim to address critical manufacturing needs and enhance the pharmaceutical supply chain against a backdrop of regional growth and demand for biologics and novel therapies.